JPWO2020223435A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020223435A5 JPWO2020223435A5 JP2021564373A JP2021564373A JPWO2020223435A5 JP WO2020223435 A5 JPWO2020223435 A5 JP WO2020223435A5 JP 2021564373 A JP2021564373 A JP 2021564373A JP 2021564373 A JP2021564373 A JP 2021564373A JP WO2020223435 A5 JPWO2020223435 A5 JP WO2020223435A5
- Authority
- JP
- Japan
- Prior art keywords
- rsv
- pharmaceutical composition
- monoclonal antibody
- antigen
- binding fragment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000427 antigen Substances 0.000 claims description 66
- 102000036639 antigens Human genes 0.000 claims description 66
- 108091007433 antigens Proteins 0.000 claims description 66
- 239000012634 fragment Substances 0.000 claims description 66
- 239000008194 pharmaceutical composition Substances 0.000 claims description 51
- 206010061603 Respiratory syncytial virus infection Diseases 0.000 claims description 14
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 13
- 239000000872 buffer Substances 0.000 claims description 13
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 13
- 235000000346 sugar Nutrition 0.000 claims description 13
- 239000004094 surface-active agent Substances 0.000 claims description 13
- 229930006000 Sucrose Natural products 0.000 claims description 8
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 8
- 229960002885 histidine Drugs 0.000 claims description 8
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 8
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 8
- 229920000053 polysorbate 80 Polymers 0.000 claims description 8
- 229940068968 polysorbate 80 Drugs 0.000 claims description 8
- 239000005720 sucrose Substances 0.000 claims description 8
- QZNNVYOVQUKYSC-JEDNCBNOSA-N (2s)-2-amino-3-(1h-imidazol-5-yl)propanoic acid;hydron;chloride Chemical compound Cl.OC(=O)[C@@H](N)CC1=CN=CN1 QZNNVYOVQUKYSC-JEDNCBNOSA-N 0.000 claims description 5
- KWTQSFXGGICVPE-UHFFFAOYSA-N 2-amino-5-(diaminomethylideneamino)pentanoic acid;hydron;chloride Chemical compound Cl.OC(=O)C(N)CCCN=C(N)N KWTQSFXGGICVPE-UHFFFAOYSA-N 0.000 claims description 5
- 238000011993 High Performance Size Exclusion Chromatography Methods 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 238000007918 intramuscular administration Methods 0.000 claims description 3
- 150000008163 sugars Chemical class 0.000 claims description 2
- 241000725643 Respiratory syncytial virus Species 0.000 claims 27
- 206010024971 Lower respiratory tract infections Diseases 0.000 claims 7
- 230000002265 prevention Effects 0.000 claims 5
- 239000004475 Arginine Substances 0.000 claims 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 3
- 239000004472 Lysine Substances 0.000 claims 3
- 229960003121 arginine Drugs 0.000 claims 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 3
- 235000009697 arginine Nutrition 0.000 claims 3
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 3
- 208000029483 Acquired immunodeficiency Diseases 0.000 claims 2
- 208000002330 Congenital Heart Defects Diseases 0.000 claims 2
- 201000010374 Down Syndrome Diseases 0.000 claims 2
- 208000019693 Lung disease Diseases 0.000 claims 2
- 208000031951 Primary immunodeficiency Diseases 0.000 claims 2
- 206010044688 Trisomy 21 Diseases 0.000 claims 2
- 241000700605 Viruses Species 0.000 claims 2
- 230000003097 anti-respiratory effect Effects 0.000 claims 2
- 230000001684 chronic effect Effects 0.000 claims 2
- 208000028831 congenital heart disease Diseases 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 239000003443 antiviral agent Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 238000003556 assay Methods 0.000 description 20
- 238000006386 neutralization reaction Methods 0.000 description 19
- 238000000034 method Methods 0.000 description 14
- 239000000203 mixture Substances 0.000 description 11
- 230000037396 body weight Effects 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025014950A JP2025072444A (ja) | 2019-04-30 | 2025-01-31 | 抗ｒｓｖ抗体の投与レジメン及び抗ｒｓｖ抗体を含む組成物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962840701P | 2019-04-30 | 2019-04-30 | |
| US62/840,701 | 2019-04-30 | ||
| PCT/US2020/030619 WO2020223435A1 (en) | 2019-04-30 | 2020-04-30 | Dosage regimens for and compositions including anti-rsv antibodies |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025014950A Division JP2025072444A (ja) | 2019-04-30 | 2025-01-31 | 抗ｒｓｖ抗体の投与レジメン及び抗ｒｓｖ抗体を含む組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022531205A JP2022531205A (ja) | 2022-07-06 |
| JPWO2020223435A5 true JPWO2020223435A5 (https=) | 2023-05-11 |
| JP2022531205A5 JP2022531205A5 (https=) | 2023-05-11 |
Family
ID=70779897
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021564373A Pending JP2022531205A (ja) | 2019-04-30 | 2020-04-30 | 抗ｒｓｖ抗体の投与レジメン及び抗ｒｓｖ抗体を含む組成物 |
| JP2025014950A Pending JP2025072444A (ja) | 2019-04-30 | 2025-01-31 | 抗ｒｓｖ抗体の投与レジメン及び抗ｒｓｖ抗体を含む組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025014950A Pending JP2025072444A (ja) | 2019-04-30 | 2025-01-31 | 抗ｒｓｖ抗体の投与レジメン及び抗ｒｓｖ抗体を含む組成物 |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US12024553B2 (https=) |
| EP (1) | EP3962940A1 (https=) |
| JP (2) | JP2022531205A (https=) |
| KR (1) | KR20220002427A (https=) |
| CN (1) | CN113825767A (https=) |
| AU (1) | AU2020265676A1 (https=) |
| BR (1) | BR112021020846A2 (https=) |
| CA (1) | CA3138180A1 (https=) |
| CO (1) | CO2021014370A2 (https=) |
| EA (1) | EA202192776A1 (https=) |
| IL (1) | IL287443A (https=) |
| MX (1) | MX2021013248A (https=) |
| SG (1) | SG11202111748TA (https=) |
| TW (1) | TWI861099B (https=) |
| WO (1) | WO2020223435A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI761453B (zh) * | 2017-03-01 | 2022-04-21 | 英商梅迪繆思有限公司 | 抗rsv單株抗體配製物 |
| WO2023039584A2 (en) * | 2021-09-13 | 2023-03-16 | Medimmune Limited | Prevention of respiratory syncytial virus lower respiratory tract infection with nirsevimab |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1997830A1 (en) | 2007-06-01 | 2008-12-03 | AIMM Therapeutics B.V. | RSV specific binding molecules and means for producing them |
| PE20091174A1 (es) * | 2007-12-27 | 2009-08-03 | Chugai Pharmaceutical Co Ltd | Formulacion liquida con contenido de alta concentracion de anticuerpo |
| US8568726B2 (en) | 2009-10-06 | 2013-10-29 | Medimmune Limited | RSV specific binding molecule |
| LT2950886T (lt) | 2013-02-01 | 2020-07-10 | Medimmune, Llc | Respiracinio sincitinio viruso f baltymo epitopai |
| FR3008921B1 (fr) | 2013-07-23 | 2015-12-25 | Safran | Piece en materiau composite avec portion de conductivite thermique et electrique et procede de fabrication d'une telle piece |
| EP4353316A3 (en) | 2014-01-15 | 2024-08-21 | Medimmune Limited | Rsv-specific antibodies and functional parts thereof |
| BR112019018022A2 (pt) | 2017-03-01 | 2020-06-02 | Medimmune Limited | Formulações de anticorpos monoclonais |
| TWI761453B (zh) | 2017-03-01 | 2022-04-21 | 英商梅迪繆思有限公司 | 抗rsv單株抗體配製物 |
-
2020
- 2020-04-27 US US16/859,750 patent/US12024553B2/en active Active
- 2020-04-30 AU AU2020265676A patent/AU2020265676A1/en active Pending
- 2020-04-30 MX MX2021013248A patent/MX2021013248A/es unknown
- 2020-04-30 US US17/606,614 patent/US20220204593A1/en active Pending
- 2020-04-30 TW TW109114519A patent/TWI861099B/zh active
- 2020-04-30 CA CA3138180A patent/CA3138180A1/en active Pending
- 2020-04-30 EA EA202192776A patent/EA202192776A1/ru unknown
- 2020-04-30 CN CN202080032470.XA patent/CN113825767A/zh active Pending
- 2020-04-30 WO PCT/US2020/030619 patent/WO2020223435A1/en not_active Ceased
- 2020-04-30 BR BR112021020846A patent/BR112021020846A2/pt unknown
- 2020-04-30 KR KR1020217038129A patent/KR20220002427A/ko active Pending
- 2020-04-30 JP JP2021564373A patent/JP2022531205A/ja active Pending
- 2020-04-30 SG SG11202111748TA patent/SG11202111748TA/en unknown
- 2020-04-30 EP EP20727466.3A patent/EP3962940A1/en active Pending
-
2021
- 2021-10-20 IL IL287443A patent/IL287443A/en unknown
- 2021-10-26 CO CONC2021/0014370A patent/CO2021014370A2/es unknown
-
2024
- 2024-05-20 US US18/669,241 patent/US20240417447A1/en active Pending
-
2025
- 2025-01-31 JP JP2025014950A patent/JP2025072444A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017160208A5 (https=) | ||
| JPWO2021183359A5 (https=) | ||
| US20220298241A1 (en) | Use of anti-fcrn antibodies in the treatment of pemphighus and pemphigoid diseases | |
| JP2023528826A (ja) | Ｓａｒｓ関連コロナウイルスに対する中和抗体 | |
| TW200912003A (en) | Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment | |
| CN113797333A (zh) | 一种新型冠状病毒抗体的药物组合物及其用途 | |
| WO2017059813A1 (zh) | 抗乙肝表面抗原的抗体及其用途 | |
| JP2021511043A5 (https=) | ||
| EP4615579A1 (en) | Antigen binding molecules targeting sars-cov-2 | |
| JPWO2020223435A5 (https=) | ||
| US20230227555A1 (en) | Cd-3 antibodies for the treatment of coronavirus | |
| JP2024500322A (ja) | 併用療法 | |
| JP2024177399A (ja) | 呼吸器疾患の治療のための汎ｅｌｒ＋ｃｘｃケモカイン抗体 | |
| EP4164673A2 (en) | Methods and compositions related to neutralizing antibodies against human coronavirus | |
| SG11202111748TA (en) | Dosage regimens for and compositions including anti-rsv antibodies | |
| JP2023518812A (ja) | Ｃｏｖｉｄ１９肺炎を治療するための、トシリズマブとレムデシビルとの組み合わせ | |
| JPWO2019147867A5 (https=) | ||
| JPWO2021180821A5 (https=) | ||
| CN121015902A (zh) | 抗trop2抗体药物偶联物和抗pd-l1/cd47双特异抗体联合治疗肿瘤的用途 | |
| CN115531531A (zh) | 抗人vegf抗体和化疗联用在制备治疗结直肠癌药物中的用途 | |
| CN117467011A (zh) | 一种抗FcRn抗体及其制剂与应用 | |
| WO2021005232A1 (en) | Intranasal administration of neutralising antiviral antibodies | |
| EP4673433A2 (en) | Methods for treating influenza infections | |
| WO2025235420A1 (en) | Methods of treating or preventing sarbecovirus with antibodies or antigen-binding fragments thereof | |
| JP2023518815A (ja) | Ｉｌ６アンタゴニストによるｃｏｖｉｄ－１９肺炎を含む肺炎の治療方法 |